Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric Ulcer Digestive System Diseases Digestive System Neoplasms Duodenal Diseases Duodenal Ulcer Early Gastric Cancer Gastric Mucosa-associated Lymphoid Tissue (MALT) Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Lymphoma Idiopathic Thrombocytopenic Purpura Neoplasms Neoplasms by Site Peptic Ulcer Stomach Diseases Stomach Neoplasms Stomach Ulcer

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Aichi, Japan

About this study

Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer

Exclusion criteria

H.pylori negative at the time when the triple therapy is started

Treatment and study plan

Primary outcomes

Number of Adverse Drug Reactions

Time frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months

Secondary outcomes

Rate of H.Pylori eradication

Time frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication

Important dates

Study start: 2011
Primary completion: 2014
Study completion: 2014
First posted: Sep 16, 2011
Registry last updated: Apr 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed